This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides (OMEGA)

This study has been completed.
Reliant Pharmaceuticals
Information provided by:
Penn State University Identifier:
First received: July 19, 2007
Last updated: July 14, 2010
Last verified: June 2008
The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

Condition Intervention
Hypertriglyceridemia Drug: Omega-3 acid ethyl esters Other: Corn oil placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Omacor: Measures of Endothelial Function and triGleride Alteration

Resource links provided by NLM:

Further study details as provided by Penn State University:

Primary Outcome Measures:
  • Triglyceride levels and lipid profile [ Time Frame: 8 weeks ]
  • Erythrocyte fatty acids [ Time Frame: 8 weeks ]
  • Flow-mediated dilation [ Time Frame: 8 weeks ]
  • Cardiovascular reactivity [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Circulating Inflammatory Markers [ Time Frame: 8 weeks ]
  • Fasting Insulin and glucose [ Time Frame: 8 weeks ]
  • Psychosocial profile [ Time Frame: 8 weeks ]

Enrollment: 28
Study Start Date: July 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
4 g P-OM3
Drug: Omega-3 acid ethyl esters
4 g P-OM3
Experimental: 2
1 g P-OM3
Drug: Omega-3 acid ethyl esters
4 g P-OM3
Placebo Comparator: 3 Other: Corn oil placebo
4 g Placebo


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • triglycerides 150-500 mg/dL
  • aged 21-65
  • generally healthy
  • BMI 20-39

Exclusion Criteria:

  • smoking
  • premenopausal (if female)
  • use of hormone replacement or oral contraceptives
  • use of lipid lowering or blood pressure medication
  • hypertension (BP > 150/95)
  • peripheral vascular disease
  • heart disease, diabetes, or stroke
  • inflammatory disease (e.g. rheumatoid arthritis or crohn's)
  • elevated liver enzymes
  • high intake of omega-3 containing foods
  • allergy to adhesive or latex
  • use of aspirin, anticoagulants, or SSRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00504309

United States, Pennsylvania
Penn State University General Clinical Research Center
University Park, Pennsylvania, United States, 16802
Sponsors and Collaborators
Penn State University
Reliant Pharmaceuticals
Principal Investigator: Sheila G West, PhD Penn State University
Principal Investigator: Penny M Kris-Etherton, PhD Penn State University
Principal Investigator: Ann C Skulas-Ray, B.S. Penn State University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sheila West, Ph.D., Penn State University Identifier: NCT00504309     History of Changes
Other Study ID Numbers: G214
Study First Received: July 19, 2007
Last Updated: July 14, 2010

Keywords provided by Penn State University:
eicosapentaenoic acid
docosahexaenoic acid
flow mediated dilation
Moderate hypertriglyceridemia

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on July 19, 2017